Technical Analysis for RUBY - Rubius Therapeutics, Inc.

Grade Last Price % Change Price Change
C 23.88 -1.04% -0.25
RUBY closed down 1.04 percent on Friday, April 9, 2021, on 18 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical RUBY trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -1.04%
Wide Bands Range Expansion -1.04%
Oversold Stochastic Weakness -1.04%
Fell Below 20 DMA Bearish 0.08%
1,2,3 Pullback Bullish Bullish Swing Setup 0.08%
Older End-of-Day Signals for RUBY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance 1 day ago
60 Minute Opening Range Breakout 2 days ago
Up 2% 2 days ago
Down 1% 2 days ago
Up 1% 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Rubius Therapeutics, Inc. Description

Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Autoimmune Disease Application Software Autoimmunity Therapies For Cancer Red Blood Cell Gout Computer Aided Engineering Phenylketonuria Pku Therapeutic Applications Cystinuria Enzyme Replacement Therapies Homocystinuria Rtx

Is RUBY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 38.71
52 Week Low 4.2
Average Volume 2,156,938
200-Day Moving Average 8.94
50-Day Moving Average 17.50
20-Day Moving Average 25.25
10-Day Moving Average 24.75
Average True Range 3.14
ADX 50.39
+DI 33.15
-DI 11.70
Chandelier Exit (Long, 3 ATRs ) 29.29
Chandelier Exit (Short, 3 ATRs ) 24.01
Upper Bollinger Band 31.65
Lower Bollinger Band 18.85
Percent B (%b) 0.39
BandWidth 50.69
MACD Line 2.10
MACD Signal Line 2.79
MACD Histogram -0.6909
Fundamentals Value
Market Cap 1.93 Billion
Num Shares 80.9 Million
EPS -1.70
Price-to-Earnings (P/E) Ratio -14.08
Price-to-Sales 0.00
Price-to-Book 3.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.52
Resistance 3 (R3) 25.62 25.19 25.24
Resistance 2 (R2) 25.19 24.77 25.13 25.15
Resistance 1 (R1) 24.53 24.51 24.32 24.43 25.06
Pivot Point 24.10 24.10 23.99 24.04 24.10
Support 1 (S1) 23.44 23.68 23.23 23.34 22.70
Support 2 (S2) 23.01 23.42 22.95 22.61
Support 3 (S3) 22.35 23.01 22.52
Support 4 (S4) 22.25